Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis committee is expected to discuss the increased risk of infections when Orencia (abatacept) is used in combination with other biologic rheumatoid arthritis therapies during the Sept. 6 review of Bristol's drug.